Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

American Journal of Physiology - Endocrinology and Metabolism logoLink to American Journal of Physiology - Endocrinology and Metabolism
. 2020 Jun 1;318(6):E890–E891. doi: 10.1152/ajpendo.00195.2020

Reply to Jakovac; Severity of COVID-19 infection in patients with phenylketonuria: is vitamin D status protective?

Júlio César Rocha 1,2,, Conceição Calhau 1,2, Anita MacDonald 3
PMCID: PMC7276976  PMID: 32479158

to the editor: In his outstanding article, Jakovac (7) highlighted the relevance of vitamin D in coronavirus disease (COVID-19) context. In fact, this seems an important metabolic explanation for the higher vulnerability for severe forms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the patients with obesity and hypertension or older patients. There are no published intervention studies to prove that vitamin D supplementation could help with COVID-19 outcomes. However, our group specializing in phenylketonuria (PKU; McKusick #261600) are unaware of any reported deaths from COVID-19 in this patient group. Could it be that patients with PKU are spared from COVID-19 severe outcomes? A proof of concept that vitamin D status could effectively help infected individuals with the new coronavirus might be fostered from this observation.

In fact, for many patients with PKU, a phenylalanine-restricted diet remains the only management strategy, despite emerging pharmacological treatments. It is established that stringent dietary treatment accomplishes near-normal outcomes (14). Dietary management involves a controlled phenylalanine intake, supplemented with a low phenylalanine protein substitute, usually containing micronutrients (12). Initially, nutritional requirements were not fully understood, and unpalatable medical formulas without rigorous supplementation led to nutritional deficiencies (10). In recent years, the quality of dietary treatment has considerably improved, protein substitutes are fortified with micronutrients to meet requirements, and there are few reports of micronutrient inadequacy in PKU (8). Balanced nutrition is required for optimal cell function with vitamins A, B6, B12, C, D, E, folate, trace elements, and essential fatty acids important and complementary in supporting the immune system (1).

Although vitamin D deficiency is common in the general population, several recent studies reported good or improved vitamin D status in patients with PKU, dependent on the amount of protein substitute being consumed. A patient, taking 60 g/day protein equivalent from protein substitute will receive around 13 to 30 µg/day of vitamin D compared with a requirement varying between 10 to 15 µg/day for adults (3, 15). In the United Kingdom, Daly et al. (2) reported median 25-hydroxy-vitamin D levels above 80 nmol/L in 50 PKU diet-treated patients aged 5 to 16 yr. At the end of 1 yr intervention, no patient had a vitamin D concentration of ≤50 nmol/L. Also, in adults with PKU, the vitamin D intake was significantly higher in diet-adherent compared with nonadherent patients (25.8 ± 8.96 vs. 4.16 ± 5.31 μg/day, respectively; P < 0.001) (6). Thiele et al. (16) showed in patients with PKU that vitamin D intake decreased to less than requirements when protein substitute intake was lowered as a consequence of pharmacological treatment. A recent, retrospective study from early treated adults with PKU patients from 17 European centers highlighted a low number (n = 32 of 173) of patients with low vitamin D status (25-OH vitamin D <50 nmol/L) (9). Experience from Portugal comparing a group of patients with PKU with healthy controls showed vitamin D inadequacy was more prevalent in the control group (13).

Although there is no direct evidence that vitamin D will prevent or treat COVID-19, vitamin D may help (5). Data from the University of Turin, Italy, indicated a high prevalence of hypovitaminosis D in hospitalized patients with COVID-19 (4). In PKU, associated with the nutrient supplementation in protein substitutes, it is possible that satisfactory vitamin D status offers protection against COVID-19. This, of course, is speculation, and COVID-19 incidence in patients with PKU within and between countries is not reported. To understand if nutritional status may influence acute respiratory infection rate in COVID-19, it seems important to study the occurrence of COVID-19 in adolescent and adult patients with PKU and compare outcome with their treatment status. In addition, individual susceptibility to vitamin D deficiency and dose response of supplementation strategies should be based on assessing single nucleotide polymorphisms (SNPs) in vitamin D metabolism (11, 17).

DISCLOSURES

J. C. Rocha is member of the European Nutrition Expert Panel (Biomarin) and of the advisory boards of Applied Pharma Research and Nutricia. He has received speaker’s fees from Applied Pharma Research, Merck Serono, BioMarin, Nutricia, Vitaflo, Cambrooke, PIAM, and Lifediet. A. MacDonald has received research funding and honoraria from Nutricia, Vitaflo International and Merck Serono. She is a member of the European Nutritionist Expert Panel (Biomarin), a member of Sapropterin Advisory Board (Biomarin), a member of the advisory board entitled ELEMENT (Danone-Nutricia), and a member of an advisory board for Arla and Applied Pharma Research. None of the other authors has any conflicts of interest, financial or otherwise, to disclose.

AUTHOR CONTRIBUTIONS

J.C.R. drafted manuscript; J.C.R., C.C., and A.M. edited and revised manuscript; J.C.R., C.C., and A.M. approved final version of manuscript.

REFERENCES

  • 1.Calder PC, Carr AC, Gombart AF, Eggersdorfer M. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. Nutrients 12: E1181, 2020. doi: 10.3390/nu12041181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Daly A, Evans S, Chahal S, Santra S, Pinto A, Jackson R, Gingell C, Rocha J, Van Spronsen FJ, MacDonald A. Glycomacropeptide: long-term use and impact on blood phenylalanine, growth and nutritional status in children with PKU. Orphanet J Rare Dis 14: 44, 2019. doi: 10.1186/s13023-019-1011-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.EFSA NDA Panel (EFSA Panel on Dietetic Products, Nutrition and Allergies) Dietary reference values for vitamin D. EFSA J 14: 4547, 2016. doi: 10.2903/j.efsa.2016.4547. [DOI] [Google Scholar]
  • 4.Isaia G. Possibile ruolo preventivo e terapeutico della vitamina D nella gestione della pandemia da COVID-19. https://www.unitonews.it/storage/2515/8522/3585/Ipovitaminosi_D_e_Coronavirus_25_marzo_2020.pdf [Accessed 21 May 2020].
  • 5.Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that vitamin d supplementation could reduce risk of influenza and covid-19 infections and deaths. Nutrients 12: E988, 2020. doi: 10.3390/nu12040988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Green B, Browne R, Firman S, Hill M, Rahman Y, Kaalund Hansen K, Adam S, Skeath R, Hallam P, Herlihy I, Jenkinson F, Nicol C, Adams S, Gaff L, Donald S, Dawson C, Robertson L, Fitzachary C, Chan H, Slabbert A, Dunlop C, Cozens A, Newby C, Bittle V, Hubbard G, Stratton R. Nutritional and metabolic characteristics of UK adult phenylketonuria patients with varying dietary adherence. Nutrients 11: 2459, 2019. doi: 10.3390/nu11102459. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Jakovac H. COVID-19 and vitamin D—Is there a link and an opportunity for intervention? Am J Physiol Endocrinol Metab 318: E589, 2020. doi: 10.1152/ajpendo.00138.2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lammardo AM, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A, Dokoupil K, Ozel HG, Goyens P, Feillet F. Main issues in micronutrient supplementation in phenylketonuria. Mol Genet Metab 110, Suppl: S1–S5, 2013. doi: 10.1016/j.ymgme.2013.08.008. [DOI] [PubMed] [Google Scholar]
  • 9.Lubout CMA, Arrieta Blanco F, Bartosiewicz K, Feillet F, Gizewska M, Hollak C, van der Lee JH, Maillot F, Stepien KM, Wagenmakers MAEM, Welsink-Karssies MM, van Spronsen FJ, Bosch AM. Bone mineral density is within normal range in most adult phenylketonuria patients. J Inherit Metab Dis 43: 251–258, 2020. doi: 10.1002/jimd.12177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Pena MJ, de Almeida MF, van Dam E, Ahring K, Bélanger-Quintana A, Dokoupil K, Gokmen-Ozel H, Lammardo AM, MacDonald A, Robert M, Rocha JC. Protein substitutes for phenylketonuria in Europe: access and nutritional composition. Eur J Clin Nutr 70: 785–789, 2016. doi: 10.1038/ejcn.2016.54. [DOI] [PubMed] [Google Scholar]
  • 11.Revez JA, Lin T, Qiao Z, Xue A, Holtz Y, Zhu Z, Zeng J, Wang H, Sidorenko J, Kemper KE, Vinkhuyzen AAE, Frater J, Eyles D, Burne THJ, Mitchell B, Martin NG, Zhu G, Visscher PM, Yang J, Wray NR, McGrath JJ. Genome-wide association study identifies 143 loci associated with 25 hydroxyvitamin D concentration. Nat Commun 11: 1647, 2020. doi: 10.1038/s41467-020-15421-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Rocha JC, Macdonald A. Treatment options and dietary supplements for patients with phenylketonuria. Expert Opin Orphan Drugs 6: 667–681, 2018. doi: 10.1080/21678707.2018.1536541. [DOI] [Google Scholar]
  • 13.Rocha JC, Silva N, van Spronsen FJ, Almeida MF, Borges N, Guimarães JT. Serum vitamin D levels in patients with phenylketonuria. J Inherit Metab Dis 38: S91–S92, 2015. [Google Scholar]
  • 14.Romani C, Manti F, Nardecchia F, Valentini F, Fallarino N, Carducci C, De Leo S, MacDonald A, Palermo L, Leuzzi V. Adult cognitive outcomes in phenylketonuria: explaining causes of variability beyond average Phe levels. Orphanet J Rare Dis 14: 273, 2019. doi: 10.1186/s13023-019-1225-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.The Scientific Advisory Committee on Nutrition (SACN) SACN vitamin D and health report. [Online]. https://www.gov.uk/government/groups/scientific-advisory-committee-on-nutrition [2 May 2020].
  • 16.Thiele AG, Rohde C, Mütze U, Arelin M, Ceglarek U, Thiery J, Baerwald C, Kiess W, Beblo S. The challenge of long-term tetrahydrobiopterin (BH4) therapy in phenylketonuria: Effects on metabolic control, nutritional habits and nutrient supply. Mol Genet Metab Rep 4: 62–67, 2015. doi: 10.1016/j.ymgmr.2015.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Zhang M, Zhao LJ, Zhou Y, Badr R, Watson P, Ye A, Zhou B, Zhang J, Deng HW, Recker RR, Lappe JM. SNP rs11185644 of RXRA gene is identified for dose-response variability to vitamin D3 supplementation: a randomized clinical trial. Sci Rep 7: 40593, 2017. doi: 10.1038/srep40593. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Physiology - Endocrinology and Metabolism are provided here courtesy of American Physiological Society

RESOURCES